Together with a fellow colleague, Felipe Tapia, they aim for the commercial development of a virus manufacturing platform with the potential of revolutionazing the gene therapy field by making these treatments affordable to the general population. The use of viral vectors for gene therapies has shown the promise to become the next medical revolution for combating a wide variety of currently untreatable diseases with current treatments costing several hundred thousand US dollars.

This project will combine a continuous bioreactor developed by Pavel's colleague and a low-cost purification system developed by Pavel.

Read more: <link http: www.contivir.com external-link-new-window external link in new>www.contivir.com